Status:
COMPLETED
Double Blind Atorvastatin Amlodipine Study
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Angina
Eligibility:
All Genders
21-80 years
Phase:
PHASE4
Brief Summary
To evaluate and compare the safety and efficacy of amlodipine, atorvastatin and the combination in patients with symptomatic myocardial ischemia. Amlodipine's use in angina has been well documented i...
Eligibility Criteria
Inclusion
- Holter monitoring at baseline which demonstrates a total of 15 minutes of ischemia and/or 3 ischemic events per 48 hours.
- Total cholesterol \> 5.2 mmol/L (200 mg/dL) on diet alone.
Exclusion
- Myocardial infarction within 2 months prior to the study.
- Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol.
Key Trial Info
Start Date :
July 1 2001
Trial Type :
INTERVENTIONAL
End Date :
January 1 2007
Estimated Enrollment :
360 Patients enrolled
Trial Details
Trial ID
NCT00159718
Start Date
July 1 2001
End Date
January 1 2007
Last Update
January 28 2021
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Rijeka, Croatia
2
Pfizer Investigational Site
Zagreb, Croatia
3
Pfizer Investigational Site
Ostrava-Kunčice, Czechia
4
Pfizer Investigational Site
Pilsen, Czechia